EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Alemtuzumab for haematological malignancies

Ning An, Kangqi Bian, Chunrui Li

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06344-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2025. Verfasst von Ning An und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030…. Hauptthemen laut MEDLINE: Alemtuzumab, Hematologic Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alemtuzumab is a humanized recombinant monoclonal antibody that specifically targets the CD52 antigen, which is expressed on both malignant and normal T and B lymphocytes. By binding to CD52, alemtuzumab exerts potent antitumor and immunosuppressive effects. Initially approved by the FDA in 2001 for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), alemtuzumab's therapeutic applications have expanded to various hematologic malignancies, including lymphoma, acute leukemia, myelodysplastic syndromes (MDS), aplastic anemia (AA), graft-versus-host disease (GVHD), and chimeric antigen receptor T-cell (CAR-T) therapy. This review evaluates the efficacy and safety of alemtuzumab in these conditions, aiming to synthesize current evidence and provide guidance for clinical practice to optimize the use of alemtuzumab in the treatment of these diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlemtuzumabHematologic NeoplasmsAntineoplastic Agents, ImmunologicalHumansCD52 AntigenGraft vs Host DiseaseMyelodysplastic SyndromesAnemia, AplasticLeukemia, Lymphocytic, Chronic, B-Cell

Stichwörter der Autor:innen

AlemtuzumabEfficacyGraft-versus-host diseaseHematologic malignanciesSafety

Substanzen

AlemtuzumabAntineoplastic Agents, ImmunologicalCD52 AntigenCD52 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, China.
  • Nanjing Bioheng Biotech Co., Ltd., Nanjing, China.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, China. cunrui5650@hust.edu.cn.
  • Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. cunrui5650@hust.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province

Zitieren

APA

An, N., Bian, K., & Li, C. (2025). Alemtuzumab for haematological malignancies. Annals of Hematology. https://doi.org/10.1007/s00277-025-06344-8

Vancouver

An N, Bian K, Li C. Alemtuzumab for haematological malignancies. Annals of Hematology. 2025. doi:10.1007/s00277-025-06344-8

BibTeX
@article{An2025,
  author = {An, Ning and Bian, Kangqi and Li, Chunrui},
  title = {Alemtuzumab for haematological malignancies},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06344-8}
}
Kostenlos starten →